Cargando…

Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment

Although some studies have reported prognostic factors for coronavirus disease 2019 (COVID-19), they were conducted before standard treatment with remdesivir and dexamethasone was implemented. This retrospective, observational study was conducted to evaluate various prognostic factors in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yu Jung, Song, Joon Young, Hyun, Hakjun, Nham, Eliel, Yoon, Jin Gu, Seong, Hye, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508954/
https://www.ncbi.nlm.nih.gov/pubmed/36197235
http://dx.doi.org/10.1097/MD.0000000000030474
_version_ 1784797129769746432
author Choi, Yu Jung
Song, Joon Young
Hyun, Hakjun
Nham, Eliel
Yoon, Jin Gu
Seong, Hye
Noh, Ji Yun
Cheong, Hee Jin
Kim, Woo Joo
author_facet Choi, Yu Jung
Song, Joon Young
Hyun, Hakjun
Nham, Eliel
Yoon, Jin Gu
Seong, Hye
Noh, Ji Yun
Cheong, Hee Jin
Kim, Woo Joo
author_sort Choi, Yu Jung
collection PubMed
description Although some studies have reported prognostic factors for coronavirus disease 2019 (COVID-19), they were conducted before standard treatment with remdesivir and dexamethasone was implemented. This retrospective, observational study was conducted to evaluate various prognostic factors in patients with COVID-19 pneumonia receiving standard treatment with remdesivir and dexamethasone. Of 99 patients with COVID-19 pneumonia, 68 (68.7%) died within 30 days of hospitalization. The mean age was 71.3 years. Remdesivir and dexamethasone were administered to 80 (80.8%) and 84 (84.8%) patients, respectively. Early antibiotic treatment was administered to 70 patients (70.7%) within 5 days of hospitalization. Dexamethasone (79.4% vs 96.8%, P = .033) was more frequently administered in the survived group, whereas early antibiotics (60.3% vs 93.5%, P = .001) were less frequently administered. In the multivariate analysis, a high National Early Warning Score (NEWS; odds ratio [OR] 1.272), high Charlson Comorbidity Index (CCI; OR 1.441), and dyspnea (OR 4.033) were independent risk factors for 30-day mortality. There was no significant difference in age, sex, and vaccination doses between the survived and fatal groups. Lymphopenia, monocytopenia and high levels of C-reactive protein (CRP)/lactate dehydrogenase (LDH) reflected poor prognosis. NEWS, CCI, and dyspnea were predictors of 30-day mortality in patients with COVID-19 pneumonia. Early antibiotic use did not lower the 30-day mortality risk.
format Online
Article
Text
id pubmed-9508954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95089542022-09-26 Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment Choi, Yu Jung Song, Joon Young Hyun, Hakjun Nham, Eliel Yoon, Jin Gu Seong, Hye Noh, Ji Yun Cheong, Hee Jin Kim, Woo Joo Medicine (Baltimore) Research Article Although some studies have reported prognostic factors for coronavirus disease 2019 (COVID-19), they were conducted before standard treatment with remdesivir and dexamethasone was implemented. This retrospective, observational study was conducted to evaluate various prognostic factors in patients with COVID-19 pneumonia receiving standard treatment with remdesivir and dexamethasone. Of 99 patients with COVID-19 pneumonia, 68 (68.7%) died within 30 days of hospitalization. The mean age was 71.3 years. Remdesivir and dexamethasone were administered to 80 (80.8%) and 84 (84.8%) patients, respectively. Early antibiotic treatment was administered to 70 patients (70.7%) within 5 days of hospitalization. Dexamethasone (79.4% vs 96.8%, P = .033) was more frequently administered in the survived group, whereas early antibiotics (60.3% vs 93.5%, P = .001) were less frequently administered. In the multivariate analysis, a high National Early Warning Score (NEWS; odds ratio [OR] 1.272), high Charlson Comorbidity Index (CCI; OR 1.441), and dyspnea (OR 4.033) were independent risk factors for 30-day mortality. There was no significant difference in age, sex, and vaccination doses between the survived and fatal groups. Lymphopenia, monocytopenia and high levels of C-reactive protein (CRP)/lactate dehydrogenase (LDH) reflected poor prognosis. NEWS, CCI, and dyspnea were predictors of 30-day mortality in patients with COVID-19 pneumonia. Early antibiotic use did not lower the 30-day mortality risk. Lippincott Williams & Wilkins 2022-09-23 /pmc/articles/PMC9508954/ /pubmed/36197235 http://dx.doi.org/10.1097/MD.0000000000030474 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Choi, Yu Jung
Song, Joon Young
Hyun, Hakjun
Nham, Eliel
Yoon, Jin Gu
Seong, Hye
Noh, Ji Yun
Cheong, Hee Jin
Kim, Woo Joo
Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
title Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
title_full Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
title_fullStr Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
title_full_unstemmed Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
title_short Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
title_sort prognostic factors of 30-day mortality in patients with covid-19 pneumonia under standard remdesivir and dexamethasone treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508954/
https://www.ncbi.nlm.nih.gov/pubmed/36197235
http://dx.doi.org/10.1097/MD.0000000000030474
work_keys_str_mv AT choiyujung prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT songjoonyoung prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT hyunhakjun prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT nhameliel prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT yoonjingu prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT seonghye prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT nohjiyun prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT cheongheejin prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment
AT kimwoojoo prognosticfactorsof30daymortalityinpatientswithcovid19pneumoniaunderstandardremdesiviranddexamethasonetreatment